Jiangsu Kanion Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 1996-05-08
- Employees
- 5.4K
- Market Cap
- -
- Website
- http://shop.kanion.com
Clinical Trials
12
Active:0
Completed:6
Trial Phases
4 Phases
Phase 1:2
Phase 2:1
Phase 4:6
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 4
6 (54.5%)Not Applicable
2 (18.2%)Phase 1
2 (18.2%)Phase 2
1 (9.1%)A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
Not Applicable
Not yet recruiting
- Conditions
- Chikungunya Fever
- Interventions
- Drug: Reduning injectionDrug: The simulant of Reduning Injection
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT07126171
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection
Phase 1
Not yet recruiting
- Conditions
- Acute Ischemic Stroke (AIS)
- Interventions
- Drug: Single dose, AAPB by injection, intravenous drip.Other: Single dose, placebo, intravenous drip.Drug: Multiple dosing, AAPB for injection, intravenous dripOther: Multiple dosing, placebo, IV drip
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06679998
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
A Prospective Cohort Study of Compound Nanxing Zhitong Ointment
- Conditions
- Chronic Musculoskeletal Pain
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Target Recruit Count
- 3000
- Registration Number
- NCT05201365
Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT05192304
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.
Phase 4
Completed
- Conditions
- Allergy
- Interventions
- Drug: 0.1mg/ml Ginkgolides Meglumine InjectionDrug: 1mg/ml Ginkgolides Meglumine InjectionDrug: 5mg/ml Ginkgolides Meglumine Injection
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Target Recruit Count
- 149
- Registration Number
- NCT02264535
- Locations
- 🇨🇳
Second Affiliated Hospital of Tianjin University of TCM, Tianjin, China
- Prev
- 1
- 2
- 3
- Next
News
No news found